BioCardia, Inc. (BCDA)
Nasdaq · Healthcare · Biotechnology
$1.09+4.81%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $16.5M
- 52-week range
- $0.75 – $1.80
- 52-week change
- −21.21%
- EPS (trailing)
- −$0.64
Fiscal year to Dec 2025
- Revenue
- $0K (−100.00%)
- Net income
- −$8.2M
- Free cash flow
- −$7.4M
From the company’s annual report on SEC EDGAR.
About BioCardia, Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.
Headquarters: Sunnyvale, United States · 17 employees · biocardia.com